Visfatin: the missing link between intra-abdominal obesity and diabetes?
Visfatin: the missing link between intra-abdominal obesity and diabetes?
Human obesity-related diabetes and the accompanying metabolic disorders have been specifically linked to increased visceral adipose tissue mass. Understanding the differences in biology of the two human fat depots (visceral and subcutaneous) might hold the key to therapeutic strategies aimed at reducing obesity-induced insulin resistance and alleviating symptoms of the metabolic syndrome. Visfatin (pre-B-cell colony-enhancing factor, PBEF) is a novel adipokine that appears to be preferentially produced by visceral adipose tissue and has insulin-mimetic actions. Could this molecule hold the key to future treatments for type 1 and 2 diabetes? This article discusses the pros and cons of visfatin action and how it might affect future therapeutic strategies.
344-347
Sethi, Jaswinder K.
923f1a81-91e4-46cd-8853-bb4a979f5a85
Vidal-Puig, Antonio
7d46d380-1b9d-40cb-90a3-72679e143036
August 2005
Sethi, Jaswinder K.
923f1a81-91e4-46cd-8853-bb4a979f5a85
Vidal-Puig, Antonio
7d46d380-1b9d-40cb-90a3-72679e143036
Sethi, Jaswinder K. and Vidal-Puig, Antonio
(2005)
Visfatin: the missing link between intra-abdominal obesity and diabetes?
Trends in Molecular Medicine, 11 (8), .
(doi:10.1016/j.molmed.2005.06.010).
Abstract
Human obesity-related diabetes and the accompanying metabolic disorders have been specifically linked to increased visceral adipose tissue mass. Understanding the differences in biology of the two human fat depots (visceral and subcutaneous) might hold the key to therapeutic strategies aimed at reducing obesity-induced insulin resistance and alleviating symptoms of the metabolic syndrome. Visfatin (pre-B-cell colony-enhancing factor, PBEF) is a novel adipokine that appears to be preferentially produced by visceral adipose tissue and has insulin-mimetic actions. Could this molecule hold the key to future treatments for type 1 and 2 diabetes? This article discusses the pros and cons of visfatin action and how it might affect future therapeutic strategies.
This record has no associated files available for download.
More information
e-pub ahead of print date: 7 July 2005
Published date: August 2005
Identifiers
Local EPrints ID: 415408
URI: http://eprints.soton.ac.uk/id/eprint/415408
ISSN: 1471-4914
PURE UUID: 2c1ac08b-5d4a-43cb-bfdc-b554176b7f3d
Catalogue record
Date deposited: 09 Nov 2017 17:30
Last modified: 16 Mar 2024 04:31
Export record
Altmetrics
Contributors
Author:
Antonio Vidal-Puig
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
